Last reviewed · How we verify
NCT03018353: CHIP
Curing HCV in Incarcerated Patients
Phase 4 trial testing Patients receiving Sof/Vel (Epclusa) and Navigation services in Hepatitis C, Chronic in 100 participants. Status unknown.
4 March 2018
Quick facts
| Lead sponsor | San Francisco Department of Public Health |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 5 March 2017 |
| Primary completion | 4 March 2018 |
| Estimated completion | 4 June 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patients receiving Sof/Vel (Epclusa) and Navigation services — full drug profile →
Conditions studied
- Hepatitis C, Chronic — all drugs for Hepatitis C, Chronic →
Sponsor
San Francisco Department of Public Health
Who can join
18 and older, any sex, with Hepatitis C, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Curing HCV in Incarcerated Patients (CHIP) is a 1-year demonstration project that will assess the feasibility of a HCV treatment program in the San Francisco City \& County Jail. The Jail Health Services will treat 100 patients using the FDA approved combination treatment, sofosbuvir/velpatasvir, Epclusa® and will continue their treatment during incarceration and after their release (if applicable).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03018353
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C, Chronic
Currently open trials in the same condition.
- NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting
- NCT04943588 — Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs · recruiting
- NCT03520660 — People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents · Phase 4 · active not recruiting
- NCT03200379 — Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan · recruiting
Other San Francisco Department of Public Health trials
Trials by the same sponsor.
- NCT07219082 — Behavioral Safety and Fentanyl Education: BSAFE · NA · not yet recruiting
- NCT07204249 — Glutide for Ending Methamphetamine · Phase 2 · not yet recruiting
- NCT06076564 — Leveraging Psychological Autopsies to Accelerate Research Into Stimulant Overdose Mortality · completed
- NCT04614584 — Mirtazapine and Methamphetamine Drug-drug Interaction Study · Phase 1 · completed
- NCT03838510 — Repeated-dose Behavioral Intervention to Reduce Opioid Overdose · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03018353 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by San Francisco Department of Public Health
- Last refreshed: 1 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03018353.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing